Curriculum Vitae of CUG Binding Protein 1 (CELF1) in Homeostasis and Diseases: a Systematic Review
Overview
Cell Biology
Molecular Biology
Authors
Affiliations
RNA-binding proteins (RBPs) are kinds of proteins with either singular or multiple RNA-binding domains (RBDs), and they can assembly into ribonucleic acid-protein complexes, which mediate transportation, editing, splicing, stabilization, translational efficiency, or epigenetic modifications of their binding RNA partners, and thereby modulate various physiological and pathological processes. CUG-BP, Elav-like family 1 (CELF1) is a member of the CELF family of RBPs with high affinity to the GU-rich elements in mRNA, and thus exerting control over critical processes including mRNA splicing, translation, and decay. Mounting studies support that CELF1 is correlated with occurrence, genesis and development and represents a potential therapeutical target for these malignant diseases. Herein, we present the structure and function of CELF1, outline its role and regulatory mechanisms in varieties of homeostasis and diseases, summarize the identified CELF1 regulators and their structure-activity relationships, and prospect the current challenges and their solutions during studies on CELF1 functions and corresponding drug discovery, which will facilitate the establishment of a targeted regulatory network for CELF1 in diseases and advance CELF1 as a potential drug target for disease therapy.
RNA binding proteins (RBPs) on genetic stability and diseases.
Aborode A, Abass O, Nasiru S, Eigbobo M, Nefishatu S, Idowu A Glob Med Genet. 2025; 12(1):100032.
PMID: 39925443 PMC: 11803229. DOI: 10.1016/j.gmg.2024.100032.
Pan-Cancer Analysis of PTBP1 to Identify it as a Prognostic and Immunological Biomarker.
Zhao Y, Wang Y, Xia Q, He H, Mao Q, Dong H Cancer Control. 2024; 31:10732748241302865.
PMID: 39612472 PMC: 11607764. DOI: 10.1177/10732748241302865.
RNA Binding Proteins as Potential Therapeutic Targets in Colorectal Cancer.
Singh V, Singh A, Liu A, Fuchs S, Sharma A, Spiegelman V Cancers (Basel). 2024; 16(20).
PMID: 39456596 PMC: 11506615. DOI: 10.3390/cancers16203502.